Verastem: Pay

Verastem paid its 4 named executives $5.2M in total in FY2025 (Dec). CEO Daniel Paterson was paid $2.3M of that.

Pay$100 in the stock at the end of FY21 → $31
CEO pay is from each proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Pay of each named executive

Daniel PatersonPresident and Chief Executive Officer
FY2025 (Dec)
FY2024 (Dec)
FY2023 (Dec)
FY2022 (Dec)
4 years
Matthew RosFormer Chief Operating Officer
FY2025 (Dec)
FY2024 (Dec)
2 years
Daniel CalkinsChief Financial Officer
FY2025 (Dec)
FY2024 (Dec)
FY2023 (Dec)
FY2022 (Dec)
4 years
Michael Kauffman, M.D., Ph.D.President of Development
FY2025 (Dec)
FY2024 (Dec)
2 years

CEO pay against the pay peers

In FY2025 (Dec), the median CEO pay of the 5 peers with pay on file was $5.1M. The CEO of Verastem was paid $2.3M, 54% below the median.

  1. 1Scholar Rock Holding
  2. 2Cogent Biosciences
  3. 3Compass Therapeutics
  4. 4Kura Oncology
  5. 5Olema Pharmaceuticals
  6. 6Verastem
  7. 7Acrivon Therapeutics, Inc.Not disclosed
  8. 8Actinium Pharmaceuticals, Inc.Not disclosed
  9. 9Aura BiosciencesNot disclosed
  10. 10Cardiff OncologyNot disclosed
  11. 11CelcuityNot disclosed
  12. 12Cullinan Oncology, Inc.Not disclosed
  13. 13Leap Therapeutics, Inc.Not disclosed
  14. 14Lian BioNot disclosed
  15. 15MEI Pharma, Inc.Not disclosed
  16. 16Syros Pharmaceuticals, Inc.Not disclosed
  17. 17Terns Pharmaceuticals, Inc.Not disclosed
  18. 18iTeos Therapeutics, Inc.Not disclosed

Pay of each named executive comes from the Summary Compensation Table of each proxy statement. Realized pay adds the value of options used and stock that vested. CEO pay of each peer comes from its own Pay versus Performance table.